Houston, Louisiana Clinical Trials

A listing of Houston, Louisiana clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 98 clinical trials
Safety Pharmacokinetics and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

Primary Objectives: Phase 1: To characterize the safety and tolerability of isatuximab in kidney transplant candidates. Phase 2: To evaluate the efficacy of isatuximab in desensitization of patients awaiting kidney transplantation. Secondary Objectives: Phase 2: To characterize the safety profile of isatuximab in kidney transplant candidates. To characterize the pharmacokinetic …

kidney transplant
nephropathy
chronic kidney disease
isatuximab
sar650984
Investigational Site Number 8400004
 (4.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +1 other locations
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients …

urothelial carcinoma
squamous cell carcinoma of head and neck
carcinoma
non-small cell lung cancer
melanoma
The University Of Texas MD Anderson Cancer Center
 (4.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +3 other locations
Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)

The objectives of this study are to evaluate the safety, tolerability and efficacy of AT-527 in older subjects (ages 45-80 years) with moderate COVID-19 and risk factors for poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma). Eligible subjects will be randomized to blinded AT-527 (nucleotide analog) tablets or …

coronavirus infection
covid-19
acute respiratory syndrome (sars)
SARS
asthma
Atea Study Site
 (4.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +9 other locations
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

stage iv nsclc
small cell lung cancer
mek inhibitor
brain metastases
gene fusion
University of Texas M.D. Anderson Cancer Center
 (4.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +3 other locations
A Study of LY3819253 (LY-CoV555) in Participants With Mild to Moderate COVID-19 Illness

The purpose of this study is to measure how well LY3819253 works against the virus that causes COVID-19. LY3819253 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus …

gastrointestinal symptoms
sickle cell disease
lung disease
respiratory disorder
pharyngitis
Houston Methodist Research Ins
 (4.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +61 other locations
First in Human Study of M6223 in Participants With Metastatic or Locally Advanced Solid Unresectable Tumors

The main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), immunogenicity and (if observed) the maximum tolerated dose (MTD) of M6223 as a single agent (Part 1A) and of M6223 combined with bintrafusp alfa (Part 1B) in participants with metastatic or locally advanced solid unresectable tumors.

MD Anderson Cancer Center
 (4.1 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +3 other locations
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

Opaganib, a sphingosine kinase-2 (SphK2) inhibitor, has been broadly tested in Phase I/II studies. Extensive nonclinical data indicates both anti-viral and anti-inflammatory activity via selective SphK2 inhibition which may prove beneficial for treating COVID-19 infection and resulting pneumonia. This proof of concept study will take place in the US and …

coronavirus infection
covid-19
x-rays
pneumonia
oropharyngeal
Memorial Hermann, Memorial City Medical Center
 (2.4 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +4 other locations
EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement

This phase II trial investigates the effect of EXPAREL compared to lidocane as a local anesthetic in patients who are undergoing pleuroscopy with pleural biopsy and indwelling pleural catheter placement. This trial aims to see whether EXPAREL or lidocane is able to make patients more comfortable.

M D Anderson Cancer Center
 (4.1 away) Contact site
  • 0 views
  • 15 Sep, 2021
  • 1 location
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors  

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy for participants aged at least 18 years with advanced unresectable or metastatic malignancies. The study will include 2 parts: A dose escalation Part 1: for finding the recommended …

University of Texas MD Anderson Cancer Center-Site Number: 8400005
 (4.1 away)
  • 0 views
  • 24 Jun, 2026
  • 1 location
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (ATLAS-NEO)

This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory …

The Gulf States Hemophilia and Thrombophilia Center Site Number : 8400002
 (4.1 away) Contact site
  • 0 views
  • 24 May, 2024
  • +53 other locations